Pfizer names six finalists in $55 mil Lipitor review

Published on .

Most Popular
Pfizer has picked six finalists to compete for the $55 million account for its cholesterol-lowering drug Lipitor. Cline, Davis & Mann; Deutsch; Gotham; Kirshenbaum Bond & Partners; Merkley Newman Harty; and Messner Vetere Berger McNamee Schmetterer/Euro RSCG, all New York, will make presentations at the beginning of December. Consultant on the review is Advice & Advisors.

Copyright October 2000, Crain Communications Inc.

In this article: